Cargando…
Challenges for assessing replicability in preclinical cancer biology
We conducted the Reproducibility Project: Cancer Biology to investigate the replicability of preclinical research in cancer biology. The initial aim of the project was to repeat 193 experiments from 53 high-impact papers, using an approach in which the experimental protocols and plans for data analy...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651289/ https://www.ncbi.nlm.nih.gov/pubmed/34874008 http://dx.doi.org/10.7554/eLife.67995 |
_version_ | 1784611371867963392 |
---|---|
author | Errington, Timothy M Denis, Alexandria Perfito, Nicole Iorns, Elizabeth Nosek, Brian A |
author_facet | Errington, Timothy M Denis, Alexandria Perfito, Nicole Iorns, Elizabeth Nosek, Brian A |
author_sort | Errington, Timothy M |
collection | PubMed |
description | We conducted the Reproducibility Project: Cancer Biology to investigate the replicability of preclinical research in cancer biology. The initial aim of the project was to repeat 193 experiments from 53 high-impact papers, using an approach in which the experimental protocols and plans for data analysis had to be peer reviewed and accepted for publication before experimental work could begin. However, the various barriers and challenges we encountered while designing and conducting the experiments meant that we were only able to repeat 50 experiments from 23 papers. Here we report these barriers and challenges. First, many original papers failed to report key descriptive and inferential statistics: the data needed to compute effect sizes and conduct power analyses was publicly accessible for just 4 of 193 experiments. Moreover, despite contacting the authors of the original papers, we were unable to obtain these data for 68% of the experiments. Second, none of the 193 experiments were described in sufficient detail in the original paper to enable us to design protocols to repeat the experiments, so we had to seek clarifications from the original authors. While authors were extremely or very helpful for 41% of experiments, they were minimally helpful for 9% of experiments, and not at all helpful (or did not respond to us) for 32% of experiments. Third, once experimental work started, 67% of the peer-reviewed protocols required modifications to complete the research and just 41% of those modifications could be implemented. Cumulatively, these three factors limited the number of experiments that could be repeated. This experience draws attention to a basic and fundamental concern about replication – it is hard to assess whether reported findings are credible. |
format | Online Article Text |
id | pubmed-8651289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-86512892021-12-09 Challenges for assessing replicability in preclinical cancer biology Errington, Timothy M Denis, Alexandria Perfito, Nicole Iorns, Elizabeth Nosek, Brian A eLife Cancer Biology We conducted the Reproducibility Project: Cancer Biology to investigate the replicability of preclinical research in cancer biology. The initial aim of the project was to repeat 193 experiments from 53 high-impact papers, using an approach in which the experimental protocols and plans for data analysis had to be peer reviewed and accepted for publication before experimental work could begin. However, the various barriers and challenges we encountered while designing and conducting the experiments meant that we were only able to repeat 50 experiments from 23 papers. Here we report these barriers and challenges. First, many original papers failed to report key descriptive and inferential statistics: the data needed to compute effect sizes and conduct power analyses was publicly accessible for just 4 of 193 experiments. Moreover, despite contacting the authors of the original papers, we were unable to obtain these data for 68% of the experiments. Second, none of the 193 experiments were described in sufficient detail in the original paper to enable us to design protocols to repeat the experiments, so we had to seek clarifications from the original authors. While authors were extremely or very helpful for 41% of experiments, they were minimally helpful for 9% of experiments, and not at all helpful (or did not respond to us) for 32% of experiments. Third, once experimental work started, 67% of the peer-reviewed protocols required modifications to complete the research and just 41% of those modifications could be implemented. Cumulatively, these three factors limited the number of experiments that could be repeated. This experience draws attention to a basic and fundamental concern about replication – it is hard to assess whether reported findings are credible. eLife Sciences Publications, Ltd 2021-12-07 /pmc/articles/PMC8651289/ /pubmed/34874008 http://dx.doi.org/10.7554/eLife.67995 Text en © 2021, Errington et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Cancer Biology Errington, Timothy M Denis, Alexandria Perfito, Nicole Iorns, Elizabeth Nosek, Brian A Challenges for assessing replicability in preclinical cancer biology |
title | Challenges for assessing replicability in preclinical cancer biology |
title_full | Challenges for assessing replicability in preclinical cancer biology |
title_fullStr | Challenges for assessing replicability in preclinical cancer biology |
title_full_unstemmed | Challenges for assessing replicability in preclinical cancer biology |
title_short | Challenges for assessing replicability in preclinical cancer biology |
title_sort | challenges for assessing replicability in preclinical cancer biology |
topic | Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651289/ https://www.ncbi.nlm.nih.gov/pubmed/34874008 http://dx.doi.org/10.7554/eLife.67995 |
work_keys_str_mv | AT erringtontimothym challengesforassessingreplicabilityinpreclinicalcancerbiology AT denisalexandria challengesforassessingreplicabilityinpreclinicalcancerbiology AT perfitonicole challengesforassessingreplicabilityinpreclinicalcancerbiology AT iornselizabeth challengesforassessingreplicabilityinpreclinicalcancerbiology AT nosekbriana challengesforassessingreplicabilityinpreclinicalcancerbiology |